New drug combo targets Hard-to-Treat prostate cancer

NCT ID NCT07115446

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing two experimental drugs together in men with advanced prostate cancer that has worsened after standard hormone therapy. HS-20093 is an antibody-drug conjugate that targets a protein on cancer cells, while HRS-5041 is a drug that breaks down androgen receptors. The study will enroll 63 participants to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HS-20093 (an antibody-drug conjugate) and HRS-5041 (a protein degrader targeting androgen receptors)
What this could lead to
If successful, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early phase 1 trial with only 63 participants, so it is primarily testing safety and dosing. The combination may not work well or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.